Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.48 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 6/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.41 |
| ▸ | PLK1 | P53350 | 4/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491222 | 0.82 | SCN9A (0.43) | SCN9AKCNH2SCN5ASYKDOT1L | |
| SCHEMBL4482243 | 0.77 | MKNK1 (0.45) | SCN9AKCNH2SCN5ADOT1L | |
| SCHEMBL19297759 | 0.76 | SCN9A (0.41) | SCN9AKCNH2SCN5ASYKDOT1L | |
| SCHEMBL19297753 | 0.76 | KDR (0.50) | SYKKDRPTK2AURKBAKT1 | |
| SCHEMBL5419669 | 0.72 | KDM4E (0.44) | KCNH2KDR | |
| SCHEMBL25168417 | 0.72 | SYK (0.47) | SYKDOT1LKDRPTK2PLK1 | |
| SCHEMBL31258620 | 0.72 | SYK (0.47) | SYKDOT1LKDRPTK2PLK1 | |
| SCHEMBL29833329 | 0.70 | SCN9A (0.54) | SCN9AKCNH2SCN5ASYKKDR | |
| SCHEMBL29430395 | 0.69 | SLC2A1 (0.62) | SCN9AKCNH2SCN5ASYKDOT1L | |
| SCHEMBL4477255 | 0.69 | SLC2A1 (0.62) | SCN9AKCNH2SCN5ASYKDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318687-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-7560466-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070225495-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7122542-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050209224-A1 | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225495-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TYMS, TPMT | SCN9A 4443/4885KCNH2 3065/4885SCN5A 3969/4885 |
| US-20090318687-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | SSB, TYMS, TPMT | SCN9A 4443/4885KCNH2 3065/4885SCN5A 3969/4885 |
| US-20050209224-A1 | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | SSB, TYMS, TPMT | SCN9A 4443/4885KCNH2 3065/4885SCN5A 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.